Table 2.
Baseline characteristics of study cohort after propensity score matching
| Variable | HCQ-AZM group (N = 173) | Matched-control group (N = 173) | p value |
|---|---|---|---|
| Age (years) | 57 ± 13 | 57 ± 17 | 0.91 |
| Male gender | 114 (65%) | 103 (59%) | 0.19 |
| BMI | 35.3 ± 8.7 | 33.3 ± 9.9 | 0.14 |
| Coronary artery disease [n (%)] | 18 (10%) | 22 (13%) | 0.57 |
| Hypertension [n (%)] | 67 (39%) | 80 (46%) | 0.23 |
| DM type 2 [n (%)] | 46 (26%) | 41 (24%) | 0.68 |
| Chronic kidney disease [n (%)] | 49 (28%) | 44 (25%) | 0.67 |
| Stroke or TIA [n (%)] | 9 (5%) | 7 (4%) | 0.7 |
| Atrial fibrillation [n (%)] | 5 (3%) | 6 (3%) | 0.94 |
| Beta-blocker medication [n (%)] | 11 (6.3%) | 15 (8.5%) | 0.51 |
| Baseline LVEF (%) | 56.9 ± 16.3 | 53.2 ± 15.8 | 0.28 |
HCQ-AZM hydroxychloroquine and azithromycin, DM diabetes mellitus, TIA transient ischemic attack, LVEF left ventricular ejection fraction, BMI body mass index, CAD coronary artery disease
Baseline characteristics included in the propensity score model as independent variables were age, male gender, BMI, coronary artery disease, hypertension, DM, chronic kidney disease, baseline LVEF